1. Home
  2. VSECU vs CAPR Comparison

VSECU vs CAPR Comparison

Compare VSECU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VSE Corporation Tangible Equity Units

VSECU

VSE Corporation Tangible Equity Units

N/A

Current Price

$53.93

Market Cap

1.6B

Sector

N/A

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

BUY

Current Price

$28.70

Market Cap

1.6B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
VSECU
CAPR
Founded
N/A
2005
Country
United States
United States
Employees
1600
231
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
VSECU
CAPR
Price
$53.93
$28.70
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
27.6K
773.2K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.45
$4.30
52 Week High
$65.93
$40.37

Technical Indicators

Market Signals
Indicator
VSECU
CAPR
Relative Strength Index (RSI) 69.20 51.22
Support Level $44.69 $27.52
Resistance Level $58.94 $30.21
Average True Range (ATR) 3.47 1.33
MACD 1.08 0.26
Stochastic Oscillator 81.20 76.59

Price Performance

Historical Comparison
VSECU
CAPR

About VSECU VSE Corporation Tangible Equity Units

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: